Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The company has studied nearly 5,000 genes through its Genome5000™ program, identifying over 100 protein targets with significant therapeutic potential [2] - Lexicon is commercially launching INPEFA® (sotagliflozin) in the United States and has a pipeline of drug candidates in various stages of development for conditions such as neuropathic pain, diabetes, and metabolism [2] Upcoming Events - Lexicon management will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 12:30 PM ET [1] - The company will also attend the 2024 Cantor Fitzgerald Global Healthcare Conference on September 17, 2024, at 8:35 AM ET [1] - A simultaneous webcast for these events will be available on the Lexicon website, with recordings accessible for two weeks post-event [1]